■ 氏名
佐竹 悠良 (サタケ ヒロナガ)
SATAKE Hironaga

■ 所属部局/職名
Research and Education Faculty, Medical Sciences Cluster, Clinical Medicine Unit/Professor
教育研究部 医療学系 臨床医学部門/教授

■ 学部・学科・コース等
Medical School, School Hospital, Clinical Department
医学部附属病院 診療科 腫瘍内科

■ 連絡先
住 所高知県南国市岡豊町小蓮
電 話088-888-0388
F A X
E-Mailim92●kochi-u.ac.jp    (送信の際は“●”を半角の“@”に変更して送信してください。)
U R Lhttp://www.kochi-u.ac.jp/kms/courses/54/

■ 出身大学院・研究科等

■ 出身学校・専攻等
兵庫医科大学 (医学部 ) 2004 ()

■ 取得学位
京都大学博士(医学) () 京都大学

■ 研究職歴
2004-2006 八尾徳洲会総合病院 初期研修 初期研修医
2006-2009 神戸市立医療センター中央市民病院 後期研修 後期研修医
2009-2012 国立がん研究センター東病院 消化管内科 レジデント
2012-2018 神戸市立医療センター中央市民病院 腫瘍内科 副医長
2018-2021 関西医科大学附属病院 がんセンター 学長特命准教授
2021- 高知大学医学部 腫瘍内科 教授

■ 委員歴・役員歴
2020- 日本がん治療認定医機構 JBCT教育委員会委員

■ 受賞学術賞
Oral free paper prize (2011) 国外

■ 所属学会
日本内科学会
 (認定医、専門医、指導医 2007- 国内)
日本旅行学会
 (認定医 2007- 国内)
日本救急医学会
 (専門医 2010- 国内)
日本消化器病学会
 (専門医 2012- 国内)
日本臨床腫瘍学会
 (専門医、指導医、協議員 2013- 国内)
日本プライマリ・ケア連合学会
 (認定医、指導医 2014- 国内)
日本消化器内視鏡学会
 (専門医、指導医 2013- 国内)
日本肝臓学会
 (専門医 2014- 国内)
日本消化管学会
 (専門医、指導医、代議員 2014- 国内)
日本食道学会
 (認定医 2017- 国内)
ASCO
 ( 2013- 国外)
ESMO
 ( 2018- 国外)
日本がん治療認定医機構(JBCT)
 (教育委員会委員 大腸がん講師 2020- 国内)

■ 専門分野

■ 主な研究テーマ・活動

■ 研究についてのPR

■ 社会人・生徒を対象として可能な講演・授業(例えば講演題目)

■ 研究業績(論文・解説)
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
 Oncologist (Satake H, Hashida H, Tanioka H, Miyake Y, Yoshioka S, Watanabe T, Matsuura M, Kyogoku T, Inukai M, Kotake T, Okita Y, Matsumoto T, Yasui H, Kotaka M, Kato T, Kaihara S, Tsuji A) /, 2021 ()

Phase Ib/II Study of Biweekly TAS ‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS study)
 Oncologist (Satake H, Kato T, Oba K, Kotaka M, Kagawa Y, Yasui H, Nakamura M, Watanabe T, Matsumoto T, Kii T, Terazawa T, Makiyama A, Takano N, Yokota M, Okita Y, Matoba K, Hasegawa H, Tsuji A, Komatsu Y, Yoshino T, Yamazaki K, Mishima H, Oki E, Nagata N, Sakamoto J) 25/, 2020 ()

Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
 BMC Cancer (Satake H, Ando K, Oki E, Shimokawa M, Makiyama A, Saeki H, Tsuji A, Mori M) 20/, 2020 ()

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
 Cancer Chemother Pharmacol (Satake H, Sagawa T, Fujikawa K, Hatachi Y, Yasui H, Kotaka M, Kato T, Tsuji A) 82/, 2018 ()

Phase I Study of imary: Treatment with 5-FU, Oxaliplatin, Irinotecan, Levofolinate, and Panitumumab Combination Chemotherapy in Patients with Advanced/Recurrent Colorectal Cancer Involving the Wild-type RAS Gene: the JACCRO CC-14 Study
 Int J Clin Oncol (Satake H, Tsuji A, Nakamura M, Ogawa M, Kotake T, Hatachi Y, Yasui H, Takagane A, Okita Y, Nakamura K, Onikubo T, Takeuchi M, Fujii M) 23/, 2018 ()

Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI)
 ESMO Open (Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y,Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A) 2/, 2017 ()

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
 PLoS One (Ogata M, Kotaka M, Ogata T, Hatachi Y, Yasui H, Kato T, Tsuji A, Satake H) /, e0234314 2020 (学術雑誌)

A placebo controlled, double blind, randomized study of recombinant thrombomodulin (ART123) to prevent oxaliplatin induced peripheral neuropathy.
 Cancer Chemother Pharmacol (Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I) 86/, 607 2020 (学術雑誌)

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
 JAMA Oncol (Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J) 6/, 1571 2020 (学術雑誌)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
 BMC Cancer (Miyo M, Kato T, Yoshino T, Yamanaka T, Bando H, Satake H, Yamazaki K, Taniguchi H, Oki E, Kotaka M, Oba K, Miyata Y, Muro K, Komatsu Y, Baba H, Tsuji A) 20/, 687 2020 (学術雑誌)

Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer.
 Cancer Chemother Pharmacol (Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H,Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K:Kito Y, Satake H, Taniguchi H, Yamada T, Horie Y, Esaki T, Denda T, Yasui H, Izawa N, Masuishi T, Moriwaki T, Mori K, Yamazaki K) 86/, 277 2020 (学術雑誌)

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
 Cancer Chemother Pharmacol (Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M) 85/, 217 2020 (学術雑誌)

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
 Clin Colorectal Cancer (Suzuki T, Sukawa Y, Imamura CK, Masuishi T, Satake H, Kumekawa Y, Funakoshi S, Kotaka M, Horie Y, Kawai S, Okuda H, Terazawa T, Kondoh C, Kato K, Yoshimura K, Ishikawa H, Hamamoto Y, Boku N, Takaishi H, Kanai T) 19/, 13 2020 (学術雑誌)

Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
 Cancer Med (Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K) 9/, 972 2020 (学術雑誌)

Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma.
 Int J Clin Oncol (Nomura M, Oze I, Masuishi T, Yokota T, Satake H, Iwasawa S, Kato K, Andoh M) 25/, 972 2020 (学術雑誌)

Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
 Int J Clin Oncol (Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J) 25/, 1835 2020 (学術雑誌)

Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
 Int J Clin Onco (Kotaka M, Iwamoto S, Satake H, Sakai D, Kudo T, Fukunaga M, Konishi K, Ide Y, Ikumoto T, Tsuji A, Sano Y, Kato T, Sugimoto N, Satoh T, Kanazawa A, Kurata T, Yamanaka T, Tomita N) 25/, 1515 2020 (学術雑誌)

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
 Eur J Cancer (Munemoto Y, Nakamura M, Takahashi M, Kotaka M, Kuroda H, Kato T, Minagawa N, Noura S, Fukunaga M, Kuramochi H, Touyama T, Takahashi T, Miwa K, Satake H, Kurosawa S, Miura T, Mishima H, Sakamoto J, Oba K, Nagata N) 119/, 158 2019 (学術雑誌)

Safety and effectivess of FOLFOXIRI plus molecular target drug therapy for metastatic colorectal cancer: A multicenter retrospective study.
 Oncotarget (Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, Hashida H, Hamada M, Yasui H) 10/, 1070 2019 (学術雑誌)

Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treatedmetastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
 Int J Clin Oncol (Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K Mishima H) 24/, 836 2019 (学術雑誌)

The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
 BMC Cancer (Tanioka H, Nagasaka T, Uno F, Inoue M, Okita H, Katata Y, Kanzaki H, Kuramochi H, Satake H, Shindo Y, Doi A, Nasu J, Yamashita H, Yamaguchi Y) 19/, 941 2019 (学術雑誌)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.
 World J Gastrointest Oncol (Sunakawa Y, Satake H, Ichikawa W) 10/, 528 2018 (学術雑誌)

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
 Eur J Cancer (Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC)) 105/, 41 2018 (学術雑誌)

A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
 Ann Surg (Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T; Kansai Hepato-Biliary Oncology (KHBO) Group) 270/, 230 2019 (学術雑誌)

Evaluation of health-related quality of life via the Computer-Based Health Evaluation System (CHES) for Japanese metastatic breast cancer patients: a single-center pilot study.
 Breast Cancer (Kikawa Y, Hatachi Y, Rumpold G, Tokiwa M, Takebe S, Ogata T, Satake H, Kato H, Tsuji A, Yasui H, Holzner B) 26/, 255 2019 (学術雑誌)

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
 Asia Pac J Clin Oncol (Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, Yasui H, Hashida T, Kaihara S, Inokuma T, Tsuji A) 15/, 63 2019 (学術雑誌)

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
 Oncotarget (Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi.K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T) 10/, 18811 2018 (学術雑誌)

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation,JACCRO CC-11.
 Oncotarget (Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T) 9/, 30023 2018 (学術雑誌)

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a retrospective study.
 Oncotarget (Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, Yasui H) 9/, 34520 2018 (学術雑誌)

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
 Clin Colorectal Cancer (Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E) 17/, e687 2018 (学術雑誌)

A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
 Cancer Med (Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K) 7/, 4217 2018 (学術雑誌)

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
 Cancer Chemother Pharmacol (Yanagimoto H, Toyokawa H, Sakai D, Wada H, Satoi S, Yamamoto T, Nagano H, Toyoda M, Ajiki T, Satake H, Tsuji A, Miyamoto A, Tsujie M, Takemura S, Yanagihara K, Ioka T) 81/, 461 2018 (学術雑誌)

Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
 Leukemia & Lymphoma (Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, Yoshioka S, Morimoto T, Ishikawa T) 59/, 2144 2018 (学術雑誌)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
 Oncologist (Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y) 23/, 7 2018 (学術雑誌)

Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104).
 Cancer Chemother Pharmacol (Satake H, Iwatsuki M, Uenosono Y, Shiraishi T, Tanioka H, Saeki H, Sugimachi  K, Kitagawa D, Shimokawa M, Oki E, Emi Y, Kakeji Y, Tsuji A, Akagi Y, Natsugoe S, Baba H, Maehara Y) 79/, 147 2017 (学術雑誌)

Phase I study of neoadjuvant chemotherapy with capecitabine and oxaliplatin for locally advanced gastric cancer.
 Anticancer Res. (Satake H, Kondo M, Mizumoto M, Kotake T, Okita Y, Ogata T, Hatachi Y, Yasui H, Miki A, Imai Y, Ichikawa C, Murotani K, Kotaka M, Kato T, Kaihara S, Tsuji A) 37/, 3703 2017 (学術雑誌)

First-line chemotherapy with capecitabine/ oxalipatin for advanced gastric cancer: A phase I study.
 Mol Clin Oncol (Satake H, Yasui H, Kotake T, Okita Y, Hatachi Y, Kotaka M, Kato T, Tsuji A) 7/, 347 2017 (学術雑誌)

A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
 Int J Clin Oncol (Ando K, Emi Y, Suenaga T, Hamanoue M, Maekawa S, Sakamoto Y, Kai S, Satake H, Shimose T, Shimokawa M, Saeki H, Oki E, Sakai K, Akagi Y, Baba H, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC)) 22/, 913 2017 (学術雑誌)

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
 Cancer Chemother Pharmacol (Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T,   Chin K, Zenda S, Kojima T, Bando H, Yamazaki T, Iwasa S, Honma Y, Hamauchi  S, Tsushima T, Ohtsu A) 78/, 91 2016 (学術雑誌)

Clinical outcome after endoscopic resection for superficial pharyngeal squamous cell carcinoma invading the subepithelial layer.
 Endoscopy (Satake H, Yano T, Muto M, Minashi K, Yoda Y, Kojima T, Oono Y, Ikematsu H, Aoyama I, Morita S. Miyamoto S, Fujii S, Yoshizawa A, Ochiai A, Hayashi R, Kaneko K) 47/, 11 2015 (学術雑誌)

First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naïve metastatic colorectal cancer (J1-TRIBE study).
 Cancer Treatment Communications (Satake H, Tsuji A, Kotake T, Okita Y, Hatachi Y) 4/, 75 2015 (学術雑誌)

Feasibility of salvage endoscopic resection for patients with locoregional failure after definitive radiotherapy for pharyngeal cancer.
 Endosc Int Open (Satake H, Yano T, Yoda Y, Fujii S, Zenda S, Tomioka T, Shinozaki T, Miyazaki   M, Kaneko K, Hayashi R) 3/, E274 2015 (学術雑誌)

Feasibility of Outpatient Chemotherapy with S-1 and Cisplatin for Gastric Cancer.
 Journal of Cancer Therapy (Satake H, Tsuji A, Kotake T, Fujita M) 5/, 759 2014 (学術雑誌)

Radial incision and cutting method for refractory stricture after nonsurgical treatment of esophageal cancer.
 Endoscopy (Yano T, Yoda Y, Satake H, Kojima T, Yagishita A, Oono Y, Ikematsu H, Kaneko K) 45/, 316 2013 (学術雑誌)

Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
 Oncology (Kaneko K, Yano T, Minashi K, Kojima T, Ito M, Satake H, Yajima Y, Yoda Y, Ikematsu H, Oono Y, Hayashi R, Onozawa M, Ohtsu A) 84/, 57 2013 (学術雑誌)

Early Clinical Outcomes of Anal Squamous Cell Carcinoma Treated with Concurrent Chemoradiotherapy with 5-Fluorouracil Plus Mitomycin C in Japanese Patients: Experience at a Single Institution.
 Jpn J Clin Oncol (Satake H, Yoshino T, Sasaki T, Bando H, Yod Y, Ikematsu H, Kojima T, Fuse N,    Zenda S, Doi T, Kaneko K, Ohtsu A) 42/, 861 2012 (学術雑誌)

Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer.
 Gastrointest Endosc (Muto M, Satake H, Yano T, Minashi K, Hayashi R, Fujii S, Ochiai A, Ohtsu A, Morita S, Horimatsu T, Ezoe Y, Miyamoto S, Asato R, Tateya I, Yoshizawa A, Chiba T) 74/, 477 2011 (学術雑誌)

Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
 Gastric Cancer. (Iwatsuki M, Orita H, Kobayashi K, Hidaka S, Arigami T, Kusumoto T, Satake H, Oki E, Tsutsumi S, Tobimatsu K, Shimokawa M, Saeki H, Makiyama A, Baba H, Mori M.) 25/, 180 2022 (学術雑誌)

Curative resection of ureteral metastasis of rectal cancer: a case report and review of literature.
 Clin J Gastroenterol. (Matsui Y, Hamada M, Matsumi Y, Sekimoto M, Ishida M, Satake H, Kurokawa H, Kinoshita H. ) 15/, 151 2022 (学術雑誌)

Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab.
 Case Rep Oncol. (Yoshida T, Miki H, Satake H, Kobayashi T, Matsumi Y, Hamada M, Boku S, Shibata N, Ishida M, Sekimoto M.) 14/, 1497 2021 (学術雑誌)

Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial.
 Palliat Med Rep. (Miura T, Okizaki A, Hasuo H, Satomi E, Tagami K, Imai K, Kojima T, Satake H, Ishiki H, Inoue A, Yamaguchi T.) 17/, 316 2021 (学術雑誌)

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12).
 Oncol Ther. (Nakamura M, Satake H, Sagawa T, Takagane A, Sekikawa T, Oguchi K, Kaji T, Takeuchi M, Ichikawa W, Fujii M.) 9/, 635 2021 (学術雑誌)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Patients With Active Cancer.
 In Vivo (Ogata M, Ama Y, Ogata T, Hirabatake M, Yasui H, Satake H) 35/, 2747 2021 (学術雑誌)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
 Invest New Drugs. (Kotani D, Yoshino T, Kotaka M, Kawazoe A, Masuishi T, Taniguchi H, Yamazaki K, Yamanaka T, Oki E, Muro K, Komatsu Y, Bando H, Satake H, Kato T, Tsuji A) 39/, 1649 2021 (学術雑誌)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
 BMC Cancer (Ikoma T, Shimokawa M, Kotaka M, Matumoto T, Nagai H, Boku S, Shibata N, Yasui H,Satake H) 21/, 518 2021 (学術雑誌)

Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
 Int J Clin Oncol. (Kato T, Kuboki Y, Gamoh M, Komatsu Y, Yasui H, Satake H, Oki E, Tanioka H, Kotaka M, Makiyama A, Denda T, Goto M, Yoshino T, Yamazaki K, Soeda J, Shibuya K, Iwata M, Oba K, Yamaguchi K) 26/, 1238 2021 (学術雑誌)

Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy.
 Cancer Chemother Pharmacol (Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I) 87/, 585 2021 (学術雑誌)

Disagreement between patient- and physician-reported outcomes on symptom adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
 Cancer Med (Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K) 9/, 9419 2020 (学術雑誌)

Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naive Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602.
 Oncologist (Terazawa T, Kato T, Goto M, Ohta K, Noura S, Satake H, Kagawa Y, Kawakami H,Hasegawa H, Yanagihara K, Shingai T, Nakata K, Kotaka M, Hiraki M, Konishi K, Nakae S, Sakai D, Kurokawa Y, Shimokawa T, Satoh T) 26/, 17 2021 (学術雑誌)

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).
 Cancer Chemother Pharmacol (Ishibashi K, Aoyama T, Kotaka M, Satake H, Tsuji Y, Kataoka M, Nakamura M, Nagata N, Sakamoto J, Oba K, Mishima H) 87/, 665 2021 (学術雑誌)

Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
 PLoS One (Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, Piao Y) 16/, e0246160 2021 (学術雑誌)

Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial).
 Cancer Chemother Pharmacol (Sai S, Toyoda M, Tobimatsu K, Satake H, Yasui H, Kimbara S, Koyama T, Fujishima Y, Imamura Y, Funakoshi Y, Kiyota N, Toyama H, Kodama Y, Minami H) 87/, 65 2021 (学術雑誌)

■ 研究業績(著書)
オンコロジークリニカルガイド 消化器癌化学療法 5版(2021)
 出版社:南山堂

免疫チェックポイント阻害薬 実践ガイドブック 使いこなすためのコツ!(2020)
 出版社:MEDICAL VIEW

がん治療で起こる副作用・合併症の治療法と薬剤開発(2018)
 出版社:株式会社技術情報協会

■ 研究業績(口頭・ポスター)

■ 研究業績(特許)

■ 研究業績(その他の活動)


前ページへ戻る